Kensey Nash Looking At Smaller Angio-Seal To Boost Market Share
This article was originally published in The Gray Sheet
Executive SummaryKensey Nash is predicting that the U.S. launch in January of a 6 Fr version of its Angio-Seal hemostatic puncture closure device will give the company a leg up on competitors Datascope (VasoSeal) and Perclose (ProStar and TechStar).
You may also be interested in...
NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.